OIPE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	s: Jacek MARTYNOW et al.) Group Art Unit:
Serial No	: 10/530,139)) Examiner:
Filed:	April 4, 2005) Attorney Docket No: 9558/9404) (Z-3215/05)
Internatio	nal Application No. PCT/PL20/000099) (2-3213/03)
Internatio	nal Filing Date: 1 October 2003)
17	ocess and Intermediates to Prepare B-hydroxy-7α-methyl-19-nor-)))
17	α-pregn-5(10)en-20-yn-3-one)

INFORMATION DISCLOSURE STATEMENT

Mail Stop AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The following documents relate to applicants' corresponding International Patent Application No. PCT/PL03/00099, filed October 1, 2003, International Publication No. WO 2004/031204 A2, published April 15, 2004, and are enclosed for the consideration of the U.S. Patent Examiner.

- 1. International PCT Patent Application No. PCT/PL03/00099, filed October 1, 2003, International Publication No. WO 2004/031204 A2, published April 15, 2004.
- 2. PCT International Search Report of March 17, 2004 and Notification of Transmittal thereof for PCT International Patent Application No. PCT/PL03/00099.
- 3. PCT Written Opinion of September 8, 2004, International Patent Application No. PCT/PL03/00099 for Process and Intermediates to Prepare 17β-hydroxy-7α-methyl-19-nor-17α-pregn-5(10)en-20-yn-3-one.

4. PCT International Preliminary Examination Report of December 29, 2004 and Notification of Transmittal thereof, International Patent Application No. PCT/PL03/00099 for Process and Intermediates to Prepare 17 β -hydroxy-7 α -methyl-19-nor-17 α -pregn-5(10)en-20-yn-3-one.

The patents, published applications and publications listed below were cited as references in the International Search Report of applicants' corresponding International PCT Patent Application No. PCT/PL03/00099, filed October 1, 2003, International Publication No. WO 2004/031204 A2, published April 15, 2004 or were located during a search for the subject matter of the invention. The patents and published patent applications listed below generally relate to subject matter of the invention, but do not fairly teach or suggest the claimed Process and Intermediates to Prepare 17β-hydroxy-7α-methyl-19-nor-17α-pregn-5(10)en-20-yn-3-one. Copies of the listed patents, published patent applications and publications below are enclosed for consideration by the Examiner.

- 1. Department of Organic Chemistry, Southwest Foundation for Research and Education; Dinunno, Cecil M. et al: "Methylnorethindrone 10.6: hydroperoxide: Isolation and Characterization"; *Steroids*; Volume 42, Number 4, October 1983, pp. 401-408.
- 2. Department of Chemistry, State University of New York; Robert M. Hoyte et al.; " 7α -Methyl- 17α -(E-2'-[125]Iiodovinyl)-19-nortestosterone: A new radioligand for the detection of androgen receptor:" *Steroids*; Vol. 58, January 1993, pp. 13-23.
- 3. Blye et al. U.S. Patent No. 4,308,265, granted December 29, 1981, pertains to a 7α -Methylnorethindrone Enanthate and Its Use in Long Term Suppression of Fertility in Female Mammals.
- 4. Organon, Scientific Development Group, N.P. van Vliet et al.; "An alternative synthesis of 17β-hydroxy-7α-methyl-19-nor-17α-pregn-5(10)-en-20-yn-3-one" (Org OD 14); *Recl. Trav. Chim. Pays-Bas* 105, 111-115 (1986).
- 5. International Publication No. PCT/EP99/07768, filed October 11, 1999, International Publication No. WO 00/23460, published April 27, 2000, of AKZO NOBEL N.V. for High Purity Composition Comprising $(7\alpha,17\alpha)$ -17 hydroxy-7methyl-19nor-17-Pregn-5(10)-en-20-yn3-one.
- 6. Bucourt U.S. Patent No. 3,534,139, granted October 13, 1970, pertains to 17α -Ethynyl-8 α -H- Δ ⁵⁽¹⁰⁾-Estrene-17 β -OL-3-One, Process of Preparation, Therapeutic Administration and Intermediates.

7. Hofmeister et al. U.S. Patent No. 4,945,064, granted July 31, 1990, pertains to

Estrane and Androstane Derivatives, Process for Producing Them and Preparations

Containing These Compounds.

8. Ringold et al U.S. Patent No. 2,806,030, granted September 10, 1957, pertains

to Cyclopentanophenanthrene Derivatives and Process for the Preparation Thereof.

9. Anner et al. U.S. Patent No. 3,318,928, granted May 9, 1967, pertains to 7α-

Alkyl-17α-Alkinyl-Estradiols.

10. Edwards U.S. Patent No. 3,904,611, granted September 9, 1975, pertains to

Preparation of 17α-Propadienyl Steroids.

11. Grunwell et al. U.S. Patent No. 3,928,398, granted December 23, 1975,

pertains to Derivatives of 7α-Methylestr-4-EN-3α-17β-Diol.

12. Blye et al. U.S. Patent No. 4,252,800, granted February 24, 1981, pertains to

7α-Methylnorethindrone Enanthate and its Use in Long Term Suppression of Fertility in

Female Mammals.

13. Nique et al. U.S. Patent No. 4,874,754, granted October 17, 1989, pertains to

Novel 19-Nor-Steroids.

14. Solomon et al. U.S. Patent No. 3,475,465, granted October 28, 1969, pertains

to Process for the Preparation of $\Delta^{5(10)}$ -3-Keto-19-Nor-Steroids.

Authorization is hereby given to charge any fees in connection with this Information

Disclosure Statement and this U.S. Patent Application to our Deposit Account No. 23-0920.

Respectfully submitted,

Thomas W. Tolpin

Registration Number 27,600

Attorney for Applicants

Dated: August 11, 2005

Welsh & Katz, Ltd.

Customer No. 24628

3

AUG 1 1 2005 E

PTO/SB/08A & PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ired to respond to a collection of information unless it contains a yalld OMB control number.

10/24/2001 W&K Substitute for Form PTO-SB/08A, which Substitute for form 1449A/PTO and 1449B/PTO

Sheet

Under the Paperwork Reduction

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1 of 2

Complete if Known

Application Number 10/530,139

Filing Date April 4,2 005

First Named Inventor Jacek MARTYNOW et al.

Art Unit Examiner Name

Attorney Docket Number 9558/94047 (Z-3215/05)

U.S. PATENT DOCUMENTS						
Examiner Initials*	er Cite No.1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-4,308,265	12-29-1981	Blye et al.		
		US-3,534,139	10-13-1970	Bucourt		
		US-4,945,064	07-13-1970	Hofmeister et al.		
		US-2,806,030	09-10-1957	Ringold et al.		
***************************************		US-3,318,928	05-09-1967	Anner et al.		
	I	US-3,904,611	09-09-1975	Edwards		
		US-3,928,398	12-23-1975	Grunwell et al.		
		US-4,252,800	02-24-1981	Blye et al.		
		US-4,874,754	10-17-1989	Nique et al.		
		US-3,475,465	10-28-1969	Solomon et al.		
		US-				
		US-				
		US-				
		US-				
		US-				
·		US-				
		US-				
***************************************		US				
		US-				

	FOREIGN PATENT DOCUMENTS								
Examiner Cite Initials* No.1		Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Le				
		PCT/PL03/00099 WO 2004/031204 A2	10-01-2003 04-15-2004	Przedsiebiorstwo Farmaceutyczne Anpharm S.A.					
		PCT/EP99/07768 WO 00/23460	10-11-99 04-27-2000	Akzo Nobel N.V.					

Examiner	Date	
Signature	 Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A & PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	&K Substitute for Form PTO-SI		ch is a US PTO	Complete if Known			
Substitute for f	orm 1449A/PTO and 1449B/P	то		Application Number	10/530,139		
INFOR	RMATION D	ISCI	OSURF	Filing Date	April 4,2 005		
1				First Named Inventor	Jacek MARTYNOW et al.		
STATEMENT BY APPLICANT				Art Unit			
·	(use as many she	ets as	necessary)	Examiner Name			
Sheet	Sheet 2 of 2		Attorney Docket Number	9558/94047 (Z-3215/05)			

		OTHER ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		Department of Organic Chemistry, Southwest Foundation for Research and Education; Dinunno, Cecil M. et al: "Methylnorethindrone 10.6: hydroperoxide: Isolation and Characterization"; Steroids; Volume 42, Number 4, October 1983, pp. 401-408.					
		Department of Chemistry, State University of New York; Robert M. Hoyte et al.; "7α-Methyl-17α-(E-2'-[¹²⁵]Iiodovinyl)-19-nortestosterone: A new radioligand for the detection of androgen receptor:" <i>Steroids</i> ; Vol. 58, January 1993, pp. 13-23.					
		Organon, Scientific Development Group, N.P. van Vliet et al.; "An alternative synthesis of 17β-hydroxy-7α-methyl-19-nor-17α-pregn-5(10)-en-20-yn-3-one" (Org OD 14); Recl. Trav. Chim. Pays-Bas 105, 111-115 (1986).					
		PCT International Search Report of March 17, 2004 and Notification of Transmittal thereof for PCT International Patent Application No. PCT/PL03/00099.					
		PCT Written Opinion of September 8, 2004, International Patent Application No. PCT/PL03/00099 for Process and Intermediates to Prepare 17β-hydroxy-7α-methyl-19-nor-17α-pregn-5(10)en-20-yn-3-one.					
310000000000000000000000000000000000000		PCT International Preliminary Examination Report of December 29, 2004 and Notification of Transmittal thereof, International Patent Application No. PCT/PL03/00099 for Process and Intermediates to Prepare 17β-hydroxy-7α-methyl-19-nor-17α-pregn-5(10)en-20-yn-3-one.					

Examiner	Date	
Signature	 Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Certificate of Express Mailing

Express Mail mailing label number EV 592966714 US

Date of Deposit: August 11, 2005

I hereby certify that the enclosed INFORMATION DISCLOSURE STATEMENT is being deposited with the United States Postal Service Express Mail Post Office to Addressee. Service under 37 CFR 1.10 is on the date indicated above and addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. The person mailing this paper is:

Carl	I Sta	anley	7					
m	•	70.		1 3 7	C D	3.7 '1'	D	C 17

Typed or Printed Name of Person Mailing Paper of Fee

Signature of Person Mailing Paper or Fee